Ellenbroek Bart A, Ghiabi Bibinaz
Victoria University of Wellington, School of Psychology. P.O. Box 600, Wellington 6041, New Zealand.
Curr Pharm Des. 2015;21(26):3760-70. doi: 10.2174/1381612821666150605105325.
In spite of almost 60 years of experience with the pharmacological treatment of schizophrenia, there is still a large unmet medical need for better control of especially the negative and cognitive symptoms of schizophrenia. One potential new avenue is the selective blockade of histamine H3 receptors (H3R). Based on a large basis of preclinical data, H3R antagonists or inverse agonists have been suggested to improve cognition in a variety of neurological and psychiatric indications. The aim of the present paper is to review the potential usefulness of H3R antagonists for the treatment of schizophrenia. Although, so far no H3R antagonist has been marketed and many phase II and III studies are still underway, the available data seem to indicate that H3R antagonists may not be primarily effective against the positive symptoms (i.e. the psychotic symptoms such as hallucinations and delusions) but may hold a promise as add-on therapy for selectively improving cognitive and perhaps negative symptoms.
尽管在精神分裂症的药物治疗方面已有近60年的经验，但对于更好地控制精神分裂症的阴性和认知症状，仍存在很大的未满足医疗需求。一个潜在的新途径是选择性阻断组胺H3受体（H3R）。基于大量临床前数据，H3R拮抗剂或反向激动剂已被建议用于改善多种神经和精神疾病的认知。本文的目的是综述H3R拮抗剂在精神分裂症治疗中的潜在效用。尽管到目前为止尚无H3R拮抗剂上市，许多II期和III期研究仍在进行中，但现有数据似乎表明，H3R拮抗剂可能对阳性症状（即幻觉和妄想等精神病性症状）并非主要有效，但作为附加疗法，可能有望选择性改善认知症状，或许还能改善阴性症状。
